Dasatinib induces a response in chronic lymphocytic leukemia

被引：12

作者：

Pitini, Vincenzo ^{[1
]}

Arrigo, Carmela ^{[1
]}

Altavilla, Giuseppe ^{[1
]}

机构：

[1] Univ Messina, I-98125 Messina, Italy

来源：

BLOOD | 2009年 / 113卷 / 02期

关键词：

D O I：

10.1182/blood-2008-09-178822

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

收藏

页码：498 / 498

页数：1

相关论文

共 4 条

[1]

c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches [J].

Hallaert, Delfine Y. H. ;

Jaspers, Annelieke ;

van Noesel, Carel J. ;

van Oers, Marinus H. J. ;

Kater, Arnon P. ;

Eldering, Eric .

BLOOD, 2008, 112 (13) :5141-5149

[2]

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines [J].

Hallek, Michael ;

Cheson, Bruce D. ;

Catovsky, Daniel ;

Caligaris-Cappio, Federico ;

Dighiero, Guillaume ;

Doehner, Hartmut ;

Hillmen, Peter ;

Keating, Michael J. ;

Montserrat, Emili ;

Rai, Kanti R. ;

Kipps, Thomas J. .

BLOOD, 2008, 111 (12) :5446-5456

[3]

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis [J].

Shah, Neil P. ;

Lee, Francis Y. ;

Luo, Roger ;

Jiang, Yibin ;

Donker, Marjolein ;

Akin, Cem .

BLOOD, 2006, 108 (01) :286-291

[4]

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVHgenes [J].

Veldurthy, Aditya ;

Patz, Michaela ;

Hagist, Susanne ;

Pallasch, Christian P. ;

Wendtner, Clemens-Martin ;

Hallek, Michael ;

Krause, Guenter .

BLOOD, 2008, 112 (04) :1443-1452